Thank you for registering for the cITP webinar! Go beyond the workshop to learn more about Controversies, Implications, Therapeutic Management, & Pipeline Agents in Chronic ITP with these resources below. Register for this FREE 1 hour CE Program here. You can also rewatch the program here. 

FACULTY

Useful References for Your Library

• cITP Management Summary
• International Consensus Statement
• Misdiagnosis of ITP
• Front-Line MMF Data: Bradbury CA, et al. Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia. N Engl J Med 2021;385:885-95.

Additional Resources

• Sample IVIG Dosing Policy (Ideal Body Weight) & SBAR
• Low-dose Rituximab Data: Li Y, et al. The Efficacy and Safety of Low-Dose Rituximab in Immune Thrombocytopenia: A Systematic Review and Meta-Analysis. Platelets 2019;30:690-7.

Special Populations

• TIKI Trial: IVIG vs. Observation in Pediatrics: Heitink-Pollé KM, et al. Intravenous Immunoglobulin vs Observation in Childhood Immune Thrombocytopenia: A Randomized Controlled Trial. Blood 2018;132:883-891.
• Real World Data – TPO Agonists in Older Adults: Palandri F, et al. Real-world Use of Thrombopoietin Receptor Agonists in Older Patients with Primary Immune Thrombocytopenia. Blood 2021;138:571-83.
  Refractory
  
• How I Treat Steroid Refractory: Ghanima W, et al. How I Treat Primary ITP in Adult Patients Who Are Unresponsive to or
  Dependent on Corticosteroid Treatment. Blood 2021;137:2736-44.
• Diagnosis and Role of Combination Therapy: Miltiadous O, et al. Identifying and Treating Refractory ITP: Difficulty in
  Diagnosis and Role of Combination Treatment. Blood 2020;135:472-90.